132 related articles for article (PubMed ID: 31708769)
1. The Off-Label Use of Antineoplastics in Oncology Is Limited But Has Notable Scientific Support in a University Hospital Setting.
Herrero Fernandez M; Molina Villaverde R; Arroyo Yustos M; Navarro Expósito F; Lopez Gonzalez JL; Luque Infantes MR; Alvarez-Mon Soto M
Front Pharmacol; 2019; 10():1210. PubMed ID: 31708769
[No Abstract] [Full Text] [Related]
2. Off-Label Use of Antineoplastic Drugs to Treat Malignancies: Evidence From China Based on a Nationwide Medical Insurance Data Analysis.
Wei G; Wu M; Zhu H; Han S; Chen J; Zhai C; Shi L
Front Pharmacol; 2021; 12():616453. PubMed ID: 33897416
[No Abstract] [Full Text] [Related]
3. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusions.
Glimelius B; Bergh J; Brandt L; Brorsson B; Gunnars B; Hafström L; Haglund U; Högberg T; Janunger KG; Jönsson PE; Karlsson G; Kimby E; Lamnevik G; Nilsson S; Permert J; Ragnhammar P; Sörenson S; Nygren P
Acta Oncol; 2001; 40(2-3):135-54. PubMed ID: 11441927
[TBL] [Abstract][Full Text] [Related]
4. Off-label use of cancer therapies in women diagnosed with breast cancer in the United States.
Hamel S; McNair DS; Birkett NJ; Mattison DR; Krantis A; Krewski D
Springerplus; 2015; 4():209. PubMed ID: 25977897
[TBL] [Abstract][Full Text] [Related]
5. Comparative Assessment of Off-label and Unlicensed Drug Prescriptions in Children: FDA Versus ANSM Guidelines.
Berdkan S; Rabbaa L; Hajj A; Eid B; Jabbour H; Osta NE; Karam L; Khabbaz LR
Clin Ther; 2016 Aug; 38(8):1833-44. PubMed ID: 27392716
[TBL] [Abstract][Full Text] [Related]
6. Drugs Recommended in Adult Rheumatic Diseases, But Considered for Off-Label Use in Argentina.
Villalobos F; Matellan C; Sequeira G; Kerzberg E
Reumatol Clin (Engl Ed); 2021 Feb; ():. PubMed ID: 33640322
[TBL] [Abstract][Full Text] [Related]
7. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
[TBL] [Abstract][Full Text] [Related]
8. The Unlicensed and Off-label Prescription of Medications in General Paediatric Ward: An Observational Study.
Dornelles AD; Calegari LH; de Souza L; Ebone P; Tonelli TS; Carvalho CG
Curr Pediatr Rev; 2019; 15(1):62-66. PubMed ID: 30421680
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane, and capecitabine: a descriptive report.
Donato BM; Burns L; Willey V; Cohenuram M; Oliveria S; Yood MU
Clin Ther; 2010 Mar; 32(3):546-54. PubMed ID: 20399992
[TBL] [Abstract][Full Text] [Related]
10. Use of off-label and unlicensed drugs in the neonatal intensive care unit and its association with severity scores.
Carvalho CG; Ribeiro MR; Bonilha MM; Fernandes M; Procianoy RS; Silveira RC
J Pediatr (Rio J); 2012; 88(6):465-70. PubMed ID: 23108602
[TBL] [Abstract][Full Text] [Related]
11. Off-label drug use in oncology: a systematic review of literature.
Saiyed MM; Ong PS; Chew L
J Clin Pharm Ther; 2017 Jun; 42(3):251-258. PubMed ID: 28164359
[TBL] [Abstract][Full Text] [Related]
12. Off-label and unlicensed drug use in children population.
Moulis F; Durrieu G; Lapeyre-Mestre M
Therapie; 2018 Apr; 73(2):135-149. PubMed ID: 29580614
[TBL] [Abstract][Full Text] [Related]
13. A systematic overview of chemotherapy effects in non-small cell lung cancer.
Sörenson S; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):327-39. PubMed ID: 11441939
[TBL] [Abstract][Full Text] [Related]
14. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
15. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
16. Off-label drugs use in pediatric palliative care.
De Zen L; Marchetti F; Barbi E; Benini F
Ital J Pediatr; 2018 Nov; 44(1):144. PubMed ID: 30486873
[TBL] [Abstract][Full Text] [Related]
17. Off-label use and harmful potential of drugs in a NICU in Brazil: A descriptive study.
de Souza AS; Dos Santos DB; Rey LC; Medeiros MG; Vieira MG; Coelho HLL
BMC Pediatr; 2016 Jan; 16():13. PubMed ID: 26795213
[TBL] [Abstract][Full Text] [Related]
18. Off-label and unlicensed medicines to hospitalised children in Norway.
Teigen A; Wang S; Truong BT; Bjerknes K
J Pharm Pharmacol; 2017 Apr; 69(4):432-438. PubMed ID: 27334565
[TBL] [Abstract][Full Text] [Related]
19. Systematic review: reliability of compendia methods for off-label oncology indications.
Abernethy AP; Raman G; Balk EM; Hammond JM; Orlando LA; Wheeler JL; Lau J; McCrory DC
Ann Intern Med; 2009 Mar; 150(5):336-43. PubMed ID: 19221366
[TBL] [Abstract][Full Text] [Related]
20. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
